Tag Archives: Sun Pharma Advanced Research Company

Bio-pharmaceutical teaser from India’s Centre for Knowledge Management of Nanoscience and Technology (CNMKT)

The Dec. 13, 2012 Nanowerk Spotlight article about India’s bio-pharmaceutical industry and its nanotechnology efforts was written by Vivek Patel of India’s Centre for Knowledge Management of Nanoscience and Technology (CMKNT) and appears to be an excerpt of a larger report to be released at a later date. The article is well worth reading and might be eye-opening for some folks,

Chronic diseases such as cancer, diabetes mellitus, epilepsy, osteoporosis and cardiovascular among others are not well diagnosed, because symptoms of these diseases are often less apparent (progress slowly) than acute and communicable diseases. With the rapid urbanization and the unhealthy lifestyles, the disease profile in India is gradually shifting towards an ample growth in the chronic diseases segment. According to the World Health Organization (WHO), India has the highest number of patients with diabetes and 60 percent of the world’s cardiac patients belong to India (read more: “Background Paper: Burden of Disease in India“; pdf). It is also estimated that India has the largest number of coronary artery disease related deaths in the world. The bio-pharmaceutical industry expert says that the chronic disease-related therapeutics is the fastest growing segment in the Indian pharmaceutical market.

Patel offers an analysis of the current nanotechnology-enabled bio-pharmaceutical industry in India,

Nanotechnology-enabled bio-pharmaceutical R&D and products in the Indian industry are still in the early stages of evolution. Only modest amount of investments have been made so far and most of projects are moving through different phases of research/clinical trials (phase I-III), even though a few nano-based drug delivery systems have already reached the market. The Indian bio-pharmaceutical industry is witnessing business opportunity trends such as merger & acquisitions/takeovers/collaborations/in-licensing, increase in R&D investments, innovations in healthcare and drug delivery as well as product penetration into the tier I to tier VI markets to make significant inroads into nanomedicine and nanodiagnostics. CKMNT believes that these trends, along with the favourable macroeconomics and growth drivers, nanotechnology will propel Indian bio-pharmaceutical industry to the next level of growth. It is expected that in the next 10-20 years, market will be flooded with nano-based medicines and drug delivery systems as well as nano-enabled ultrasensitive and rapid detection devices for diagnostics and therapy.

Cientifica, an international consulting firm which specializes in emerging technologies and business, authored two analyses of the international business context for nano drug delivery systems, one is a free white paper overview and the other is a full report. The company also issued a full market report on nanotechnology-enabled medical diagnostics. (Note 1: Cientifica is offering some of its 2012 reports [the drug delivery and diagnostics reports are included in the sale] at a discount price of up to 80% until Dec. 31, 2012. Contact Cientifica at +44 7887 497630 or +44 7894 708989 or email info@cientifica.com for pricing. Special academic discounts are also available. Note 2: The FrogHeart blog does not receive any monies whatsover from Cientifica.)

Getting back to the analysis of the nanotechnology-enabled bio-pharmaceutical industry in India, Patel provides a list of the most prolific Indian companies in this sector,

Fresenius Kabi Oncology Ltd. (erstwhile Dabur Pharmaceuticals Ltd.) made its foray into the field of oncology with the launch of ‘Nanoxel’, which is a novel nanoparticle-enabled formulation of Paclitaxel in 2007. …

Lupin Ltd., one of the world’s largest producers of tuberculosis drugs, with 12 factories and six research centres in India and Japan, has launched ‘Genexol-PM’ (paclitaxel nanoparticle) nanomedicine for cancer treatment by tie-up with the South Korean company Samyang Corporation. …

Cipla Ltd., one of the world’s largest generic pharmaceutical companies with a presence in over 170 countries, has successfully developed and manufactured Paclitax Nab (nanoparticle albumin bound) product for the treatment of metastatic breast cancer in 2012.

Sun Pharma Advanced Research Company Ltd. is engaged in creating new drugs and delivery systems such as ‘Paclitaxel Injection Concentrate for Nanodispersion (PICN)’and ‘Docetaxel Injection Concentrate for Nanodispersion (DICN)’. …

In 2012, Venus Remedies Ltd. has launched two nanotechnology-enabled products for arthritis and cancer treatments, respectively. The brand Taxedol consists of Docetaxel in nanoparticle form and company claims that it gives 11 % higher cancer cell killing potential as compared to existing Docetaxel…

Cadila Healthcare Ltd. (erstwhile Zydus Cadila) has successfully developed and launched nanotechnology-based ‘Oxalgin Nanogel’ formulation for the pain management therapy (arthritis, backache, joint pain etc.).

Shasun Pharmaceuticals Ltd., the active pharmaceutical ingredients manufacturer has entered into collaboration (50:50 joint ventures) with Nanoparticle M/s. Biochem, Inc., USA to develop gold nanoparticles-enabled radioactive medicine to treat prostate cancer.

Cadila Pharmaceuticals Ltd. has established a joint venture company, CPL Biologicals Pvt. Ltd., in partnership with M/s. Novavax Inc., USA to develop, manufacture and sell nanotechnology-based novel therapeutic and prophylactic vaccines, biological therapeutics and diagnostics in India. …

As noted earlier, this article does appear to be a teaser for a more comprehensive report due at a later date,

A comprehensive report on “Indian Nanotechnology Market: Technologies, Applications and Opportunities” is slated to be released by CKMNT in the future. Interested readers may please contact Mr. Vivek Patel at vivek@ckmnt.com or info@ckmnt.com for further details.